Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib + Osimertinib in EGFR TKI-Resistant NSCLC
NCT04338243Phase 2Unknown
- Sponsor
- Haihe
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of glumetinib in non-small cell lung cancer (NSCLC), sponsored by Haihe. Status: unknown.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04338243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338243.